Asthma and metabolic syndrome: Current knowledge and future perspectives. by SERAFINO AGRUSA, L. et al.
Asthma and metabolic syndrome: Current knowledge and 
future perspectives
Laura Serafino-Agrusa, Mario Spatafora, Nicola Scichilone
Laura Serafino-Agrusa, Mario Spatafora, Nicola Scichilone, 
Dipartimento Biomedico di Medicina Interna e Specialistica, 
University of Palermo, 90146 Palermo, Italy
Author contributions: Serafino-Agrusa L, Spatafora M and 
Scichilone N contributed to this paper.
Conflict-of-interest: The authors declare no conflict of interest 
related with the manuscript. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Nicola Scichilone, MD, PhD, Dipartimento 
Biomedico di Medicina Interna e Specialistica, University of 
Palermo, via Trabucco 180, 90146 Palermo, 
Italy. nicola.scichilone@unipa.it
Telephone: +39-091-6802655 
Fax: +39-091-6882842
Received: July 31, 2014 
Peer-review started: July 31, 2014 
First decision: November 18, 2014
Revised: December 11, 2014 
Accepted: December 29, 2014
Article in press: December 31, 2014
Published online: March 16, 2015
Abstract
Asthma and obesity are epidemiologically linked; 
however, similar relationships are also observed with 
other markers of the metabolic syndrome, such as 
insulin resistance and dyslipidemia, which cannot be 
accounted for by increased body mass alone. Obesity 
appears to be a predisposing factor for the asthma 
onset, both in adults and in children. In addition, 
obesity could make asthma more difficult to control 
and to treat. Although obesity may predispose to 
increased Th2 inflammation or tendency to atopy, other 
mechanisms need to be considered, such as those 
mediated by hyperglycaemia, hyperinsulinemia and 
dyslipidemia in the context of metabolic syndrome. 
The mechanisms underlying the association between 
asthma and metabolic syndrome are yet to be 
determined. In the past, these two conditions were 
believed to occur in the same individual without 
any pathogenetic link. However, the improvement 
in asthma symptoms following weight reduction 
indicates a causal relationship. The interplay between 
these two diseases is probably due to a bidirectional 
interaction. The purpose of this review is to describe 
the current knowledge about the possible link between 
metabolic syndrome and asthma, and explore potential 
application for future studies and strategic approaches.
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Core tip: Asthma is a complex syndrome that encompasses 
multiple phenotypes. The relationship with obesity has 
been addressed in the past; however, the underlying 
mechanism of such a relationship seems to be more 
complex, and not explained by the body weight 
alone. The metabolic syndrome carries a condition of 
systemic inflammation that could potentially explain 
the influence on asthma onset and severity. This is a 
rather unexplored area that could potentially open new 
scenario in the diagnostic algorithm and in the strategic 
approach, with a more comprehensive assessment of 
the disease. 
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INTRODUCTION 
Asthma is among the most common chronic diseases 
worldwide. The disease is poorly controlled despite 
available therapies in a large proportion of patients[1], 
with long-term impairment and disability[2-4]. Among 
factors impairing the control of symptoms and the lack 
of response to treatment, obesity is to be taken into 
account, as stated by recent guidelines[5].
It is well recognized that obesity and asthma are 
epidemiologically linked[6-9]. This relationship is also 
observed between asthma and other markers of the 
metabolic syndrome, such as insulin resistance and 
hypertension that cannot be accounted for by increased 
body mass alone[9-12]. The World Health Organization 
has reported that obesity has dramatically increased 
during the last few decades. In 2009-2010, more 
than one-third of United States adults (35.7%) were 
obese[13]. In this scenario, an estimated 300000 deaths 
per year are directly attributable to obesity, mainly due 
to heart diseases, diabetes, cancer, obstructive sleep 
apnea syndrome (OSAS), arthritis, and psychological 
disturbances, leading to the concept that obesity 
represents a risk factor for several pathologies in 
different clinical conditions[14]. In this regard, overweight 
and obesity have been demonstrated to be associated 
in a dose-dependent fashion with the risk of having 
asthma[15], and obesity appears to be a predisposing 
factor for the asthma onset, both in adults and in 
children, as assessed by several cross-sectional 
studies[16]. In addition, obesity could make asthma more 
difficult to control and to treat; interestingly, weight-loss 
interventions in overweight severe asthmatic patients 
have shown substantial improvements in the clinical 
status, lung function, symptoms, and overall asthma 
control[8,17,18]. However, the mechanism linking obesity 
and asthma is still a controversial issue. 
The obese-asthma phenotype is characterized by a 
paucity of airway inﬂammation. Although obesity may 
predispose to increased Th2 inﬂammation or tendency 
to atopy, other mechanisms that are independent of 
inﬂammatory inﬂiltrates need to be considered, such 
as hyperglycaemia, hyperinsulinemia and dyslipidemia 
in the context of metabolic syndrome. Metabolic 
syndrome is defined as a syndrome that involves three 
of the following characteristics: dyslipidemia (high 
levels of apoB lipoproteins and triglycerides, and/or 
low high density lipoprotein cholesterol), an impaired 
fasting glucose metabolism, hypertension or central 
obesity[19-21]. Metabolic syndrome is directly involved 
in the increased prevalence of coronary heart disease, 
atherosclerotic diseases, and diabetes mellitus type 
2[20-22]. Other metabolic abnormalities have been 
reported in patients with metabolic syndrome (chronic 
proinflammatory and prothrombotic states, liver 
disease and sleep apnea)[20-22]. In the literature, some 
authors consider that the aforementioned criterion 
is a combination of risk factors rather than a specific 
syndrome[23]. On the other hand, epidemiological data 
reveals that there is a high prevalence of metabolic 
syndrome in both childhood and young adulthood, and 
pattern seems to be related to several inflammatory 
diseases including asthma[22]. 
EPIDEMIOLOGICAL LINK BETWEEN 
ASTHMA AND METABOLIC SYNDROME 
In obese individuals, the risk for asthma in overweight 
and obese individuals is increased and does not differ 
with gender[24,25]. In a recent report, Dandona et al[26] 
showed that in obese asthma patients, with or without 
type 2 diabetes, there is an increased expression 
of pro-inflammatory mediators. Following gastric 
bypass surgery and weight loss, the expression of the 
aforementioned mediators and plasma metabolites 
fall significantly suggesting that the pro-inﬂammatory 
effect of obesity can be downregulated upon adipose 
tissue reduction. Assad et al[27] recently showed that 
BMI predicts asthma in women more than metabolic 
sybndrome[28], however, Agrawal et al[29] suggested 
that calculation of parameters was conducted on 
entirely different scales, thereby limiting comparison 
of strength. In another study, Brumpton et al[11] 
evaluated the associations of metabolic syndrome with 
the cumulative incidence of asthma in adults in 23245 
individuals after an 11 years follow up (Nord-Trøndelag 
Health Study 1999-2008), showing that metabolic 
syndrome predisposes to. In a large mendelian 
randomization study, Granell et al[30] recently found 
that higher BMI increases the risk of asthma in non-
atopic (1.90, 95%CI: 1.19-3.03) and atopic children 
(1.37, 95%CI: 0.89-2.11).
PATHOPHYSIOLOGICAL MECHANISMS
Obesity-associated asthma is characterized by the 
presence of neutrophilic airway inﬂammation, increased 
morbidity, and resistance to corticosteroids. The 
mechanisms underlying the relationship between 
metabolic syndrome and asthma are yet to be fully 
understood[31]. In the past, these two conditions were 
believed to occur in the same individual without any 
pathogenetic link. However, the improvement of in 
asthma symptoms following weight reduction implies a 
causal relationship between obesity and asthma[32,33]. 
The interplay between these two diseases could be 
based on a bidirectional interaction. For example, obese 
asthmatics are at higher risk of metabolic syndrome as 
opposed to obese individuals who do not suffer from 
asthma, suggesting that asthma per se can increase 
the risk of developing metabolic syndrome[34]. Similarly, 
metabolic syndrome has been demonstrated to increase 
the severity of asthma[35,36]. Recently, changes in the 
expression of pro-inflammatory mediators such as 
leptin, IL-6, TNF-α, C-reactive protein and adiponectin 
have been demonstrated in obese asthmatics[37], 
implying their potential role in the pathogenesis of 
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obesity-associated asthma. However, due to the paucity 
of available literature in this area, it appears difficult to 
draw definite conclusions until additional experimental 
and epidemiological data are collected.
A cross-sectional study published by Bruno et al[38] 
recently analyzed the influence of BMI on asthma 
control in subjects with severe forms of the disease, 
demonstrating that the optimal state of asthma 
control is lower in obese than in normal weight and 
in overweight severe asthmatics and the number 
of asthma exacerbation episodes are significantly 
higher in obese than in normal or overweight severe 
asthmatics. These results may be explained with 
the inflammatory cascade that the adipose tissue 
generates. Indeed, the obese state is characterized 
by the so-called low-grade systemic inﬂammation[38]. 
Subcutaneous fat is the major source of fatty acids 
for the liver, and of free fatty acids in the circulating 
plasma[39,40]. Subcutaneous fat is related to insulin 
resistance and to visceral adipose tissue[39,40]. 
Abdominal subcutaneous fat from obese subjects 
has been reported to be an inflamed adipose state 
characterized by tissue macrophage accumulation. This 
pathologic tissue has been associated with impaired 
local vasodilatation, peripheral hyperinsulinemia, and 
insulin resistance[39-41]. Macrophage presence in the 
tissue is associated with an increase of plasma high-
sensitivity C-reactive protein (hsCRP) levels and local 
amounts of TNF-α[39,40]. The precise mechanism of this 
event remains to be elucidated; however, adipokines 
have been proposed as important endocrine mediators 
since they are related to adipose tissue function 
and modulation. The following proteins are listed as 
adipokines, which are envisaged as markers of fat 
body mass and distribution, as well as tissue function: 
(1) leptin; (2) adiponectin; (3) ghrelin; (4) vaspin; (5) 
retinol binding protein 4; (6) apelin; (7) progranulin 
and MCP-1; (8) omentin; (9) resistin and chemerin; 
and (10) fetuin[42,43]. Adipose derived hormones 
may represent molecular links between asthma and 
inflammation. For example, adiponectin is known 
to exert anti-inflammatory effects, by inhibiting the 
eosinophil functions. Indeed, pre-treatment with 
adiponectin has been demonstrated to diminish the 
eotaxin-mediated chemotactic responses, by binding 
the adiponectin receptors AdipoR1 and AdipoR2 that 
are expressed in human eosinophils[44,45]. In addition, 
adiponectin has been shown to act as a protector to 
human bronchial epithelial cell that are involved in the 
pathogenesis of asthma[46]. 
High serum levels of resistin have been recently 
documented in asthmatic children[47]. More important, 
an in vitro study showed that the resistin production 
strongly increases in obese patients with severe 
persistent asthma[48], providing support to the notion 
that resistin can be depicted as a pro-inflammatory 
cytokine mainly in severely obese asthmatics. 
Conversely, high leptin levels are associated with 
a more severe disease and this even in non-obese 
asthmatics[49,50]. Leptin can upregulate systemic 
inﬂammation and may lead to an impairment in lung 
function[51]. Increased expression and secretion of pro-
inﬂammatory cytokines such as TNF-α, IL-6, and IL-12 
were detected when exposed to leptin[52]. Also, the 
systemic inﬂammation may contribute to drive insulin 
resistance, endothelial dysfunction and high blood 
pressure conditions. The results of a survey confirmed 
that leptin levels were highly associated with asthma 
especially in premenopausal women independent of 
BMI[51]. Guler et al[53] also suggested that serum leptin 
concentrations were a predictive factor for asthma 
in boys, even after adjusting for obesity. Previously, 
leptin-mediated increased bronchial hyperactivity in 
obese mice models had been documented[32].
The changes in the adipose tissue in metabolic 
syndrome favour the production of mediators that 
modulate the transcription factors. When they are 
activated by their ligands, they are able to control 
genes that are involved in intermediate metabolism[54]. 
In this regard, peroxisome proliferator-activated 
receptors (PPAR)-gamma agonists may attenuate the 
upper airway allergic inflammation by induction of 
Treg cells and inhibiting the proliferation of effector T 
cells[55].
Diet-induced dyslipidemia may affect the trafficking 
of immune cells to the lung in diseases such as asthma[56]. 
In pulmonary physiology, circulating low density and 
high density lipoproteins (LDL and HDL) are both 
taken up by specific receptors, and consequently block 
local cholesterol biosynthesis[56]. Alveolar cholesterol 
homeostasis has been demonstrated to affect surfactant 
synthesis in normal lung physiology[56]. Conversely, HDL 
promotes surfactant production, and lung fibroblast 
growth. Adipose tissue reduction by diet or surgery, 
modulation of cholesterol, or glucose metabolism, 
has an important effect in asthmatic patients. The 
apolipoprotein E (ApoE)-low density lipoproteic receptor 
pathway appears to be involved in the pathogenesis 
of a murine model of allergic asthma[1]. However, the 
mechanism by which this protein modulates asthma 
pathogenesis has never been fully elucidated. ApoE 
has been hypothesized to as negatively modulate the 
degree of airway hyperresponsiveness[57]. Perhaps, 
this mechanism can also apply to humans. Low 
levels of serum HDL were found to be associated 
with an increased risk for asthma in adolescence[58], 
and a recent analysis on 85555 adults demonstrated 
that high triglycerides and low HDL were associated 
with wheezing, supporting their role as markers of 
inflammation[59]. Recently, the association between 
LDL and asthma was investigated by Scichilone et 
al[60], who found that in mild asthmatics, the least pro-
inﬂammatory LDL (LDL-1 and LDL-2) are lower than in 
healthy subjects, whereas the most pro-inﬂammatory 
(LDL-3 and LDL-4) are higher. In addition, the serum 
concentrations of LDL-3 (most pro-inﬂammatory) were 
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negatively associated with lung function, suggesting 
their contribution to the occurrence of the inﬂammatory 
changes of the airways[60]. Insulin excess can also 
directly alter lung cellular physiology and this would 
represent a fundamental common molecular link 
between asthma and metabolic syndrome[61]. There 
is substantial data that mechanistically links insulin 
and insulin like growth factor-1 to lung development 
and function. It is conceivable, although not proven, 
that hyperinsulinemia may lead to development of 
lung disease, particularly asthma[62]. Experimental 
studies that directly address this possibility are strongly 
advocated. 
Recent observations seem to focus on the mitochondrial 
dysfunction as main mediator of the pathogenetic link 
between metabolic syndrome and asthma. Defective 
mitochondrial biogenesis in the adipose tissue is well 
documented in metabolic syndrome[63-66]. However, 
the involvement of mitochondria alterations among 
the risk factors of metabolic syndrome and asthma is 
unknown[67-72]. 
Oxidative stress on both pulmonary and extra-
pulmonary inflammation in obesity may play a 
major role[73,74]. Oxidative stress is characterized 
by increased reactive oxygen species (ROS), which 
induce functional changes of the airways. On this 
basis, increased oxidative stress may be recognized 
as a potential mechanism by which obesity results in 
increased asthma severity. In this regard, the renin 
angiotensin aldosterone system, a potent inducer of 
oxidative stress, is often activated in patients with 
metabolic syndrome, and results in increased levels 
of angiotensin Ⅱ. Angiotensin Ⅱ seems to be able to 
determine bronchial hyperresponsiveness[75] and airway 
remodelling[76]; however, the mechanisms by which this 
occurs are not yet fully understood.
CURRENT AND FUTURE DEVELOPMENTS 
Figure 1 describes the temporal and causal relationships 
between asthma and features of metabolic syndrome. 
The role of lipoproteins in the pathogenesis of 
asthma pathogenesis supported the use of statins in 
asthmatic patients[77-83]; however, there are still some 
controversies[84-86]. Even though the aim of statin 
use in asthmatic patients is related to cholesterol 
metabolism, most of the reports have highlighted the 
anti inﬂammatory properties[77-79,86,87]. An in vitro study 
showed that lovastatin attenuates the differentiation 
and proliferation of asthmatic bronchial fibroblasts[85], 
airway smooth muscle cells[86]. Both simvastatin and 
atorvastatin treatment reduce inflammatory cells in 
sputum[86]. The mevalonate-dependent and-independent 
pathways have been identified as potential opportunities 
for novel treatments with statins in asthma develop new 
treatments for asthma[78]. Even though statin therapy 
could be beneficial for a subgroup of asthmatic patients 
that are either overweight or obese, similar important 
advantages can be obtained by diet and exercise[20,26]. 
Biphosphonates could have a beneficial effect in 
asthmatic patients; alendronate has been shown to 
have a protective effect by decreasing eosinophil airway 
inflammation by chemokine secretion, eotaxin, and 
down-regulating cytokine secretion induced by Th2 
and Th17 cells[88]. Retinoic acid[89], retinoids[90] and 
fenretidine[91] appear to have a beneficial effect on 
the inflammatory asthmatic response by decreasing 
the inflammatory milieu. As a consequence, signal 
transduction pathways inhibition by these compounds 
could decrease the occurrence of bronchial constriction. 
Further studies are required to ascertain the possible 
beneficial effect of new therapeutic elements to 
control hypertension and endocrine disorders in 
asthmatic patients with metabolic syndrome. In 
patients with severe uncontrolled or non responding 
asthma[92,93], biological therapies seem to be relevant. 
Interestingly, chemokines and chemokine receptors, 
CCR3 and CCR4, have been involved in adipose tissue 
mass increase and insulin resistance[94,95]. Thus, 
therapy involving chemokines or chemokine receptor 
inhibition could potentially provide beneficial effects 
on asthmatic patients with metabolic syndrome[96]. 
Finally, a therapeutic option in asthmatic patients with 
diabetes could be represented by thiazolidinediones, 
oral diabetes medications that selectively activate 
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Asthma
Asthma
Asthma
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Dyslipidemia
Abdominal obesity
Figure 1  Relationships between asthma and features of metabolic 
syndrome. The different conditions are divided into “before” and “after” to 
explain which occurred earlier, implying a causal association. The green arrows 
describe the temporal evolution and the time when the diseases occurred. 
Arrow 1 sets asthma as a risk factor for systemic hypertension due to the 
chronic use of corticosteroids. Arrows 2 and 3 depict the role of dyslipidemia 
and hyperinsulinemia as risk factors for asthma, due to the abnormalities of the 
lipoprotein pattern and the influence on the M2 receptors, respectively. Arrow 
4 shows the bidirectional association between asthma and obesity. Arrow 5 
summarizes the influence of the above-described associations, showing the 
tight relationship between metabolic syndrome and asthma. Also see text for 
the explanation.
1
2
3
4
5
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PPAR receptor gamma, which have potent anti-
inflammatory properties thus reducing the number of 
exacerbations[97,98]. 
CONCLUSION
The scope of the current review is to explore the 
possible link between metabolic syndrome and asthma. 
Early endocrine disturbances seem to predispose to 
severe or difficult to treat asthma. Hypertensive and 
diabetic patients should be screened for respiratory 
function in the effort to identify cases of airway 
hyperreactivity or subclinical asthma. Specifically 
designed studies are needed to address the influence 
of metabolic syndrome on asthma occurrence and 
severity, and to unveil the potential underlying common 
mechanisms. Future studies will hopefully provide 
convincing evidence on useful therapeutic schemes that 
today are still unrevealed. 
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